In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France Adds Pfizer's Bevacizumab To Biosimilars List

Executive Summary

Pfizer’s Zirabev biosimilar bevacizumab has been added to France’s list of similar biologics alongside reference brand Avastin by local medicines agency ANSM.

You may also be interested in...



France Adds Five Pegfilgrastims To Biosimilar Equivalence List

Five pegfilgrastim biosimilars have been added to a newly-created group in France’s list of similar biologics, with Neulasta as the reference brand. At the same time, the country’s ANSM medicines agency has also added further biosimilars to the list against other already-listed biologic brands, and has also created new generic groups for three molecules in its répertoire of generic equivalents.

France trials range of biosimilar incentives

French legislation setting out an ‘experiment’ to trial several different methods of incentivising biosimilar prescription in hospitals has been warmly welcomed by local generics and biosimilars association Gemme.

France adds three to similar biologics list

Avastin (bevacizumab), Humalog (insulin lispro) and Herceptin (trastuzumab) have been added to France’s list of similar biologics as reference brands for newly-created similarity groups by local medicines agency ANSM. They add a further three groups to the 11 created when ANSM introduced the list last year (Generics bulletin, 10 November 2017, page 11), taking the full list to 14 reference groups covering 45 biosimilar brands.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel